Rhett P Ketterling

List of Publications by Year
in descending order

464 papers	19,217 citations	14614 66 h-index	16605 123 g-index
465 all docs	465 docs citations	465 times ranked	15713 citing authors

#	Article	IF	Citations
1	Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. New England Journal of Medicine, 2012, 366, 1079-1089.	13.9	1,688
2	Anthracycline Dose Intensification in Acute Myeloid Leukemia. New England Journal of Medicine, 2009, 361, 1249-1259.	13.9	797
3	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood, 2014, 124, 2507-2513.	0.6	575
4	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood, 2014, 124, 1473-1480.	0.6	401
5	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. Journal of Clinical Oncology, 2018, 36, 310-318.	0.8	373
6	CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood, 2003, 102, 3093-3096.	0.6	368
7	Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood, 2005, 105, 973-977.	0.6	351
8	T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood, 2009, 114, 5136-5145.	0.6	346
9	Microduplication 22q11.2, an Emerging Syndrome: Clinical, Cytogenetic, and Molecular Analysis of Thirteen Patients. American Journal of Human Genetics, 2003, 73, 1027-1040.	2.6	327
10	FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood, 2004, 104, 3038-3045.	0.6	297
11	Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Advances, 2016, 1, 21-30.	2.5	243
12	Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood, 2006, 108, 1158-1164.	0.6	239
13	ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia, 2014, 28, 2206-2212.	3.3	237
14	Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. Journal of Clinical Oncology, 2014, 32, 1242-1248.	0.8	227
15	Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood, 2012, 119, 2100-2105.	0.6	218
16	HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology, 2010, 28, 4307-4315.	0.8	216
17	GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia, 2018, 32, 1631-1642.	3.3	213
18	Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood, 2012, 120, 2280-2289.	0.6	208

#	Article	IF	Citations
19	SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood, 2012, 119, 569-572.	0.6	203
20	Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia, 2013, 27, 1504-1510.	3.3	190
21	Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood, 2010, 116, 4077-4085.	0.6	188
22	Chromosomal Rearrangements of 6p25.3 Define a New Subtype of Lymphomatoid Papulosis. American Journal of Surgical Pathology, 2013, 37, 1173-1181.	2.1	182
23	Targeted deep sequencing in primary myelofibrosis. Blood Advances, 2016, 1, 105-111.	2.5	182
24	One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience. Mayo Clinic Proceedings, 2012, 87, 25-33.	1.4	181
25	Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. American Journal of Hematology, 2014, 89, E121-4.	2.0	176
26	Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases. Modern Pathology, 2011, 24, 1421-1432.	2.9	170
27	Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood, 2012, 120, 1290-1298.	0.6	165
28	Factor VIII gene inversions causing severe hemophilia A originate almost exclusively in male germ cells. Human Molecular Genetics, 1994, 3, 1035-1039.	1.4	161
29	Clinical correlates ofJAK2V617F allele burden in essential thrombocythemia. Cancer, 2007, 109, 2279-2284.	2.0	149
30	SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood, 2012, 120, 4168-4171.	0.6	146
31	The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood, 2014, 124, 2465-2466.	0.6	135
32	Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance. American Journal of Hematology, 2013, 88, 201-206.	2.0	134
33	Mutationâ€enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. British Journal of Haematology, 2020, 189, 291-302.	1.2	134
34	FIP1L1-PDGFRA in eosinophilic disorders: Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leukemia Research, 2006, 30, 965-970.	0.4	131
35	Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients. Leukemia, 2012, 26, 101-105.	3.3	129
36	Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a <scp>M</scp>ayo <scp>C</scp>linicâ€<scp>F</scp>rench <scp>C</scp>onsortium <scp>S</scp>tudy. American Journal of Hematology, 2014, 89, 1111-1115.	2.0	129

#	Article	IF	Citations
37	Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood, 2005, 106, 3553-3558.	0.6	117
38	DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. Blood, 2017, 130, 554-557.	0.6	110
39	Diagnosis and Management of WaldenstrÃ¶m Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	3.4	110
40	Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood, 2016, 127, 1551-1558.	0.6	105
41	Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. American Journal of Surgical Pathology, 2016, 40, 36-43.	2.1	103
42	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clinic Proceedings, 2019, 94, 599-610.	1.4	103
43	Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia, 2018, 32, 1189-1199.	3.3	102
44	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia, 2018, 32, 1200-1210.	3.3	101
45	Genetic subtyping of breast implantâ€“associated anaplastic large cell lymphoma. Blood, 2018, 132, 544-547.	0.6	99
46	Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood, 2018, 132, 1386-1398.	0.6	97
47	Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer Journal, 2016, 6, e385-e385.	2.8	96
48	Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica, 2009, 94, 380-386.	1.7	94
49	Driver mutations and prognosis in primary myelofibrosis: Mayoâ€Careggi MPN alliance study of 1,095 patients. American Journal of Hematology, 2018, 93, 348-355.	2.0	94
50	Very poor longâ€term survival in past and more recent studies for relapsed AML patients: The ECOGâ€ACRIN experience. American Journal of Hematology, 2018, 93, 1074-1081.	2.0	93
51	CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood, 2012, 120, 2297-2306.	0.6	92
52	Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. Blood Advances, 2018, 2, 370-380.	2.5	90
53	WHO-defined â€˜myelodysplastic syndrome with isolated del(5q)â€™ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia, 2010, 24, 1283-1289.	3.3	88
54	Preclinical validation of fluorescence in situ hybridization assays for clinical practice. Genetics in Medicine, 2006, 8, 16-23.	1.1	86

#	Article	IF	Citations
55	Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder. Modern Pathology, 2007, 20, 592-603.	2.9	86
56	SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. Leukemia, 2013, 27, 2100-2102.	3.3	85
57	Analysis of Intratumoral Heterogeneity and Amplification Status in Breast Carcinomas With Equivocal (2+) HER-2 Immunostaining. American Journal of Clinical Pathology, 2005, 124, 273-281.	0.4	80
58	Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia. Cancer Discovery, 2012, 2, 1004-1023.	7.7	80
59	Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines. Journal of Clinical Oncology, 2016, 34, 3502-3510.	0.8	79
60	Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood, 2018, 131, 2262-2266.	0.6	77
61	U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. Leukemia, 2018, 32, 2274-2278.	3.3	75
62	Prognostic irrelevance of ring sideroblast percentage in World Health Organizationâ€“defined myelodysplastic syndromes without excess blasts. Blood, 2012, 119, 5674-5677.	0.6	73
63	Targeted nextâ€generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSSâ€R. American Journal of Hematology, 2017, 92, 1311-1317.	2.0	73
64	Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARSâ€T) and the role of nextâ€generation sequencing. American Journal of Hematology, 2016, 91, 492-498.	2.0	70
65	Clonally Related Follicular Lymphomas and Langerhans Cell Neoplasms. American Journal of Surgical Pathology, 2013, 37, 978-986.	2.1	69
66	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-ÎºB positive feedback loop in peripheral T-cell lymphoma. Blood, 2015, 125, 3118-3127.	0.6	68
67	Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Advances, 2018, 2, 2964-2972.	2.5	68
68	Molecular Diagnosis of Ewing??s Sarcoma/Primitive Neuroectodermal Tumor in Formalin-Fixed Paraffin-Embedded Tissues by RT-PCR and Fluorescence In Situ Hybridization. Diagnostic Molecular Pathology, 2005, 14, 23-28.	2.1	65
69	ExtendingJak2V617F andMplW515 Mutation Analysis to Single Hematopoietic Colonies and B and T Lymphocytes. Stem Cells, 2007, 25, 2358-2362.	1.4	65
70	Pituitary blastoma. Acta Neuropathologica, 2008, 116, 657-666.	3.9	65
71	Primary myelodysplastic syndrome with normal cytogenetics: utility of â€˜FISH panel testingâ€™ and M-FISH. Leukemia Research, 2002, 26, 235-240.	0.4	64
72	Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. European Journal of Haematology, 2008, 80, 197-200.	1.1	64

#	Article	IF	Citations
73	Biologic and genetic characterization of the novel amyloidogenic lambda light chainâ€“secreting human cell lines, ALMC-1 and ALMC-2. Blood, 2008, 112, 1931-1941.	0.6	64
74	C-MYC Alterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology, 2011, 29, 651-659.	0.8	64
75	Section E9 of the American College of Medical Genetics technical standards and guidelines: Fluorescence in situ hybridization. Genetics in Medicine, 2011, 13, 667-675.	1.1	64
76	Targeted next generation sequencing and identification of risk factors in <scp>W</scp>orld <scp>H</scp>ealth <scp>O</scp>rganization defined atypical chronic myeloid leukemia. American Journal of Hematology, 2017, 92, 542-548.	2.0	64
77	Azacitidine with or without Entinostat for the treatment of therapyâ€related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. British Journal of Haematology, 2016, 172, 384-391.	1.2	63
78	Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. European Journal of Haematology, 2009, 83, 17-21.	1.1	61
79	New highly sensitive fluorescence in situ hybridization method to detect PML/RARA fusion in acute promyelocytic leukemia. Cancer Genetics and Cytogenetics, 2003, 145, 144-151.	1.0	60
80	ROSETTE-FORMING GLIONEURONAL TUMOR. Neurosurgery, 2009, 64, E771-E772.	0.6	60
81	Reflex fluorescent in situ hybridization testing for unsuccessful product of conception cultures: A retrospective analysis of 5555 samples attempted by conventional cytogenetics and fluorescent in situ hybridization. Genetics in Medicine, 2011, 13, 545-552.	1.1	60
82	Nextâ€generation sequencing in systemic mastocytosis: Derivation of a mutationâ€augmented clinical prognostic model for survival. American Journal of Hematology, 2016, 91, 888-893.	2.0	60
83	DNMT3A mutations are associated with inferior overall and leukemiaâ€free survival in chronic myelomonocytic leukemia. American Journal of Hematology, 2017, 92, 56-61.	2.0	60
84	Histiocytoid Sweet syndrome may indicate leukemia cutis: A novel application of fluorescence in situ hybridization. Journal of the American Academy of Dermatology, 2014, 70, 1021-1027.	0.6	59
85	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer Journal, 2020, 10, 82.	2.8	59
86	Molecular classification improves risk assessment in adult BCR-ABL1â€“negative B-ALL. Blood, 2021, 138, 948-958.	0.6	59
87	Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. European Journal of Haematology, 2009, 82, 255-259.	1.1	58
88	Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Blood, 2011, 117, 5306-5313.	0.6	58
89	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Advances, 2020, 4, 3509-3519.	2.5	58
90	Evidence that descendants of three founders constitute about 25% of hemophilia B in the united states. Genomics, 1991, 10, 1093-1096.	1.3	57

#	Article	IF	Citations
91	Pediatric histiocytic sarcoma clonally related to precursor Bâ€cell acute lymphoblastic leukemia with homozygous deletion of CDKN2A encoding p16^{INK4A}. Pediatric Blood and Cancer, 2011, 56, 307-310.	0.8	56
92	Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. American Journal of Hematology, 2018, 93, 1474-1484.	2.0	56
93	Evidence for Cytogenetic and Fluorescence In Situ Hybridization Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. Mayo Clinic Proceedings, 2010, 85, 532-537.	1.4	55
94	Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma. Blood, 2019, 133, 2776-2789.	0.6	55
95	Utility of subtelomeric fluorescent DNA probes for detection of chromosome anomalies in 425 patients. Genetics in Medicine, 2003, 5, 28-34.	1.1	52
96	ALK-1 Protein Expression and ALK Gene Rearrangements Aid in the Diagnosis of Inflammatory Myofibroblastic Tumors of the Female Genital Tract. Archives of Pathology and Laboratory Medicine, 2012, 136, 623-626.	1.2	52
97	Treatment-influenced associations of PML-RARÎ± mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood, 2012, 120, 2098-2108.	0.6	52
98	Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica, 2018, 103, 1899-1907.	1.7	52
99	Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. Blood Cancer Journal, 2019, 9, 12.	2.8	52
100	Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. American Journal of Hematology, 2019, 94, 767-779.	2.0	51
101	Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome. American Journal of Hematology, 2015, 90, 411-416.	2.0	50
102	Mutations and prognosis in myelodysplastic syndromes: karyotypeâ€adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. American Journal of Hematology, 2018, 93, 691-697.	2.0	50
103	Momelotinib therapy for myelofibrosis: a 7-year follow-up. Blood Cancer Journal, 2018, 8, 29.	2.8	49
104	Therapy relatedâ€chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. American Journal of Hematology, 2018, 93, 65-73.	2.0	49
105	The factor IX gene as a model for analysis of human germline mutations: an update. Human Molecular Genetics, 1996, 5, 1505-1514.	1.4	48
106	Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). Leukemia, 2010, 24, 1370-1372.	3.3	48
107	Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. American Journal of Hematology, 2016, 91, 503-506.	2.0	47
108	Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2017, 58, 1488-1493.	0.6	47

#	Article	IF	Citations
109	Reported in vivo splice-site mutations in the factor IX gene: Severity of splicing defects and a hypothesis for predicting deleterious splice donor mutations. Human Mutation, 1999, 13, 221-231.	1.1	46
110	Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes. Blood, 2013, 122, e33-e43.	0.6	44
111	Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. Blood Cancer Journal, 2015, 5, e275-e275.	2.8	43
112	The pattern of spontaneous germ-line mutation: relative rates of mutation at or near CpG dinucleotides in the factor IX gene. Human Genetics, 1993, 91, 496-503.	1.8	42
113	Intralymphatic Cutaneous Anaplastic Large Cell Lymphoma/Lymphomatoid Papulosis. American Journal of Surgical Pathology, 2014, 38, 1203-1211.	2.1	42
114	Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. Leukemia, 2018, 32, 1254-1258.	3.3	42
115	CCND1 rearrangements and cyclin D1 overexpression in renal oncocytomas: frequency, clinicopathologic features, and utility in differentiation from chromophobe renal cell carcinoma. Human Pathology, 2009, 40, 1296-1303.	1.1	41
116	Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. Human Pathology, 2017, 64, 19-27.	1.1	41
117	EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. Blood Cancer Journal, 2018, 8, 12.	2.8	41
118	Impact of acquired del(17p) in multiple myeloma. Blood Advances, 2019, 3, 1930-1938.	2.5	41
119	Establishment and characterization of a novel WaldenstrÃ¶m macroglobulinemia cell line, MWCL-1. Blood, 2011, 117, e190-e197.	0.6	40
120	Monocytosis in polycythemia vera: Clinical and molecular correlates. American Journal of Hematology, 2017, 92, 640-645.	2.0	40
121	Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. American Journal of Hematology, 2018, 93, 649-654.	2.0	40
122	Chromosome 8p11.2 translocations: Prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution. American Journal of Hematology, 2010, 85, 238-242.	2.0	39
123	t(8;9)(p22;p24)/PCM1-JAK2 Activates SOCS2 and SOCS3 via STAT5. PLoS ONE, 2013, 8, e53767.	1.1	39
124	Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer Journal, 2015, 5, e270-e270.	2.8	39
125	Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. European Journal of Haematology, 2015, 94, 31-36.	1.1	39
126	Natural history of multiple myeloma with de novo del(17p). Blood Cancer Journal, 2019, 9, 32.	2.8	38

#	Article	IF	Citations
127	Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma. Genes Chromosomes and Cancer, 2006, 45, 1111-1120.	1.5	37
128	Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. Human Pathology, 2010, 41, 103-106.	1.1	37
129	Chronic Lymphocytic Leukemia With t(2;14)(p16;q32) Involves the BCL11A and IgH Genes and Is Associated With Atypical Morphologic Features and Unmutated IgVH Genes. American Journal of Clinical Pathology, 2009, 131, 663-670.	0.4	36
130	Chronic Lymphocytic Leukemia With t(14;19)(q32;q13) Is Characterized by Atypical Morphologic and Immunophenotypic Features and Distinctive Genetic Features. American Journal of Clinical Pathology, 2011, 135, 686-696.	0.4	36
131	Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia. European Journal of Haematology, 2019, 102, 87-96.	1.1	35
132	A past mutation at Isoleucine397is now a common cause of moderate/mild haemophilia B. British Journal of Haematology, 1990, 75, 212-216.	1.2	34
133	Functioning Paraganglioma and Gastrointestinal Stromal Tumor of the Jejunum in Three Women. American Journal of Surgical Pathology, 2006, 30, 42-49.	2.1	34
134	Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance. American Journal of Hematology, 2017, 92, E614-E618.	2.0	34
135	Desmoplastic small round cell tumor of the central nervous system: report of two cases and review of the literature. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 431-439.	1.4	33
136	Germline mutations in the factor IX gene: a comparison of the pattern in Caucasians and non-Caucasians. Human Molecular Genetics, 1993, 2, 293-298.	1.4	32
137	Rearrangements and Amplification of IER3 (IEX-1) Represent a Novel and Recurrent Molecular Abnormality in Myelodysplastic Syndromes. Cancer Research, 2009, 69, 7518-7523.	0.4	32
138	Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. British Journal of Haematology, 2018, 183, 835-838.	1.2	32
139	Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia, 2020, 34, 656-661.	3.3	32
140	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clinical Cancer Research, 2020, 26, 6581-6588.	3.2	32
141	A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients. British Journal of Haematology, 2015, 169, 71-76.	1.2	31
142	Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons. British Journal of Haematology, 2018, 182, 594-597.	1.2	31
143	Isochromosome 12p and polysomy 12 in primary central nervous system germ cell tumors: frequency and association with clinicopathologic features. Human Pathology, 2010, 41, 232-238.	1.1	30
144	Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. American Journal of Hematology, 2013, 88, 690-693.	2.0	30

#	Article	IF	Citations
145	A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 21.	2.8	30
146	Inherited interstitial deletion of chromosomes 5p and 16q without apparent phenotypic effect: further confirmation. , 2000, 20, 144-148.		29
147	Comparison of Fluorescence In Situ Hybridization, p57 Immunostaining, Flow Cytometry, and Digital Image Analysis for Diagnosing Molar and Nonmolar Products of Conception. American Journal of Clinical Pathology, 2010, 133, 196-204.	0.4	29
148	Image Analysis of HER2 Immunohistochemical Staining. American Journal of Clinical Pathology, 2012, 137, 270-276.	0.4	29
149	Splenic small B-cell lymphoma with IGH/BCL3 translocation. Human Pathology, 2006, 37, 218-230.	1.1	28
150	Clonal relationship between precursor B-cell acute lymphoblastic leukemia and histiocytic sarcoma: A case report and discussion in the context of similar cases. Leukemia Research, 2010, 34, e71-e73.	0.4	28
151	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia, 2018, 32, 1811-1815.	3.3	28
152	Epidemiology of adult acute myeloid leukemia: Impact of exposures on clinical phenotypes and outcomes after therapy. Cancer Epidemiology, 2015, 39, 1084-1092.	0.8	27
153	Gender and survival in essential thrombocythemia: A twoâ€center study of 1,494 patients. American Journal of Hematology, 2017, 92, 1193-1197.	2.0	27
154	Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. Blood Cancer Journal, 2019, 9, 103.	2.8	27
155	An MLL-SEPT9 fusion and t(11;17)(q23;q25) associated with de novo myelodysplastic syndrome. Leukemia Research, 2007, 31, 1145-1148.	0.4	26
156	Isolated Trisomy 15. American Journal of Clinical Pathology, 2008, 129, 478-485.	0.4	26
157	Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. Annals of Hematology, 2018, 97, 1453-1462.	0.8	26
158	Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. Leukemia, 2018, 32, 2512-2518.	3.3	26
159	Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotypeâ€“phenotype associations. European Journal of Haematology, 2010, 84, 191-200.	1.1	25
160	ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis. British Journal of Haematology, 2016, 175, 534-536.	1.2	25
161	A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. Leukemia, 2018, 32, 1850-1856.	3.3	25
162	Mutations and karyotype predict treatment response in myelodysplastic syndromes. American Journal of Hematology, 2018, 93, 1420-1426.	2.0	25

#	Article	IF	Citations
163	Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. American Journal of Clinical Pathology, 2005, 124, 273-81.	0.4	25
164	Utility of peripheral blood dual color, double fusion fluorescentin situhybridization forBCR/ABLfusion to assess cytogenetic remission status in chronic myeloid leukemia. Leukemia and Lymphoma, 2006, 47, 2055-2061.	0.6	24
165	Cytogenetic abnormalities in systemic mastocytosis: WHO subcategoryâ€specific incidence and prognostic impact among 348 informative cases. American Journal of Hematology, 2018, 93, 1461-1466.	2.0	24
166	Evaluation of a commercially available focused aCGH platform for the detection of constitutional chromosome anomalies. American Journal of Medical Genetics, Part A, 2007, 143A, 2357-2370.	0.7	23
167	Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates. European Journal of Haematology, 2010, 84, 518-524.	1.1	23
168	Isolated del(5q) in myeloid malignancies: Clinicopathologic and molecular features in 143 consecutive patients. American Journal of Hematology, 2011, 86, 393-398.	2.0	23
169	Polyclonal Immunoglobulin Free Light Chain Levels Predict Survival in Myeloid Neoplasms. Journal of Clinical Oncology, 2012, 30, 1087-1094.	0.8	23
170	Conventional Karyotyping and Fluorescence In Situ Hybridization. American Journal of Clinical Pathology, 2015, 143, 873-878.	0.4	23
171	LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma. American Journal of Clinical Pathology, 2016, 145, 180-190.	0.4	23
172	Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis. Blood Cancer Journal, 2018, 8, 57.	2.8	23
173	Familial 22q11.2 deletions in DiGeorge/velocardiofacial syndrome are predominantly smaller than the commonly observed 3Mb. Genetics in Medicine, 2004, 6, 517-520.	1.1	22
174	Chromosomal rearrangements and copy number abnormalities of TP63 correlate with p63 protein expression in lung adenocarcinoma. Modern Pathology, 2015, 28, 359-366.	2.9	22
175	Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization. American Journal of Clinical Pathology, 2016, 146, 86-94.	0.4	22
176	Cytogenetic findings in <scp>WHO</scp>â€defined polycythaemia vera and their prognostic relevance. British Journal of Haematology, 2018, 182, 437-440.	1.2	22
177	High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?. Blood Cancer Journal, 2020, 10, 5.	2.8	22
178	Deletions with inversions: Report of a mutation and review of the literature. Human Mutation, 1993, 2, 53-57.	1.1	21
179	A mutation in the 3' untranslated region of the factor IX gene in four families with hemophilia B. Human Molecular Genetics, 1993, 2, 1309-1310.	1.4	21
180	Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis. American Journal of Hematology, 2017, 92, 1187-1192.	2.0	21

#	Article	IF	Citations
181	KMT2A (MLL) rearrangements observed in pediatric/young adult Tâ€lymphoblastic leukemia/lymphoma: A 10â€year review from a single cytogenetic laboratory. Genes Chromosomes and Cancer, 2018, 57, 541-546.	1.5	21
182	A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. American Journal of Hematology, 2019, 94, 111-117.	2.0	21
183	How precisely can data from transgenic mouse mutation-detection systems be extrapolated to humans?: lessons from the human factor IX gene. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1994, 307, 517-531.	0.4	20
184	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. Mayo Clinic Proceedings, 2018, 93, 1363-1374.	1.4	20
185	Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma. American Journal of Surgical Pathology, 2021, 45, 550-557.	2.1	20
186	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Advances, 2020, 4, 2236-2244.	2.5	20
187	Interphase FISH to detect PBX1/E2A fusion resulting from the der(19)t(1;19)(q23;p13.3) or t(1;19)(q23;p13.3) in paediatric patients with acute lymphoblastic leukaemia. British Journal of Haematology, 2005, 129, 45-52.	1.2	19
188	Atypical generalized eruptive histiocytosis clonally related to chronic myelomonocytic leukemia with loss of Y chromosome. Journal of Cutaneous Pathology, 2013, 40, 725-729.	0.7	19
189	FISH identifies a KAT6A/CREBBP fusion caused by a cryptic insertional t(8;16) in a case of spontaneously remitting congenital acute myeloid leukemia with a normal karyotype. Pediatric Blood and Cancer, 2017, 64, e26450.	0.8	19
190	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. Blood Cancer Journal, 2018, 8, 18.	2.8	19
191	Screening for <scp>ASXL</scp>1 and <scp>SRSF</scp>2 mutations is imperative for treatment decisionâ€making in otherwise low or intermediateâ€1 risk patients with myelofibrosis. British Journal of Haematology, 2018, 183, 678-681.	1.2	19
192	Acute leukemias harboring KMT2A/MLLT10 fusion: a 10â€year experience from a single genomics laboratory. Genes Chromosomes and Cancer, 2019, 58, 567-577.	1.5	19
193	Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. Blood Advances, 2021, 5, 2272-2278.	2.5	19
194	Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. Human Pathology, 2021, 112, 20-34.	1.1	19
195	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. American Journal of Hematology, 2021, 96, 1450-1460.	2.0	19
196	Molecular Epidemiology of Factor IX Germline Mutations in Mexican Hispanics: Pattern of Mutation and Potential Founder Effects. Thrombosis and Haemostasis, 1995, 74, 1416-1422.	1.8	19
197	Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): Clinicopathologic comparison of del(5q)-positive and -negative cases. Leukemia Research, 2008, 32, 1927-1930.	0.4	18
198	Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality. Blood, 2009, 113, 1200-1201.	0.6	18

#	Article	IF	Citations
199	Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. Leukemia Research, 2018, 71, 60-62.	0.4	18
200	Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation. Haematologica, 2019, 104, e236-e239.	1.7	18
201	A novel report of cigâ€FISH and cytogenetics in POEMS syndrome. American Journal of Hematology, 2008, 83, 840-841.	2.0	17
202	Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis. European Journal of Haematology, 2008, 80, 318-321.	1.1	17
203	Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocations. Leukemia Research, 2009, 33, 843-846.	0.4	17
204	Nearly identical near-haploid karyotype in a peritoneal mesothelioma and a retroperitoneal malignant peripheral nerve sheath tumor. Cancer Genetics and Cytogenetics, 2010, 202, 123-128.	1.0	17
205	Development of a dualâ€color, double fusion FISH assay to detect RPN1/EVI1 gene fusion associated with inv(3), t(3;3), and ins(3;3) in patients with myelodysplasia and acute myeloid leukemia. American Journal of Hematology, 2010, 85, 569-574.	2.0	17
206	Clinicopathologic and Genetic Characterization of Follicular Lymphomas Presenting in the Ovary Reveals 2 Distinct Subgroups. American Journal of Surgical Pathology, 2011, 35, 1691-1699.	2.1	17
207	The B cell antigen receptor in atypical chronic lymphocytic leukemia with t(14;19)(q32;q13) demonstrates remarkable stereotypy. International Journal of Cancer, 2011, 128, 2759-2764.	2.3	17
208	Morphologically Occult Systemic Mastocytosis in Bone Marrow. American Journal of Clinical Pathology, 2015, 144, 493-502.	0.4	17
209	Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials. Leukemia Research, 2017, 59, 55-64.	0.4	17
210	MPL-mutated essential thrombocythemia: a morphologic reappraisal. Blood Cancer Journal, 2018, 8, 121.	2.8	17
211	Marked Elevation of Serum Lactate Dehydrogenase (LDH) in Primary Myelofibrosis: Clinical and Prognostic Correlates. Blood, 2016, 128, 3113-3113.	0.6	17
212	Analysis of HER2 Gene Amplification Using an Automated Fluorescence in Situ Hybridization Signal Enumeration System. Journal of Molecular Diagnostics, 2007, 9, 144-150.	1.2	16
213	Automated Duet spot counting system and manual technologist scoring using dual-fusion fluorescence in situ hybridization (D-FISH) strategy: comparison and application to FISH minimal residual disease testing in patients with chronic myeloid leukemia. Cancer Genetics and Cytogenetics, 2007, 175, 8-18.	1.0	16
214	Primary Myelodysplastic Syndromes. Mayo Clinic Proceedings, 2015, 90, 1623-1638.	1.4	16
215	Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q). Blood Cancer Journal, 2017, 7, 658.	2.8	16
216	Characterization of a cryptic IGH/CCND1 rearrangement in a case of mantle cell lymphoma with negative CCND1 FISH studies. Blood Advances, 2019, 3, 1298-1302.	2.5	16

#	Article	IF	Citations
217	Chromosome 5q deletion: Specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution. Leukemia Research, 2008, 32, 407-411.	0.4	15
218	Prognostic Irrelevance of Ring Sideroblast Percentage in World Health Organization Defined Myelodysplastic Syndromes without Excess Blasts,. Blood, 2011, 118, 3803-3803.	0.6	15
219	Peripheral blood cytogenetic studies in myelofibrosis: Overall yield and comparison with bone marrow cytogenetic studies. Leukemia Research, 2008, 32, 1597-1600.	0.4	14
220	Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia. European Journal of Haematology, 2010, 85, 86-87.	1.1	14
221	Microgranular variant of acute promyelocytic leukemia with normal conventional cytogenetics, negative PML/RARA FISH and positive PML/RARA transcripts by RT-PCR. Cancer Genetics, 2011, 204, 522-523.	0.2	14
222	TP53 mutations and polymorphisms in primary myelofibrosis. American Journal of Hematology, 2012, 87, 204-206.	2.0	14
223	A Case of Nonleukemic Myeloid Sarcoma With FIP1L1-PDGFRA Rearrangement. American Journal of Surgical Pathology, 2013, 37, 147-151.	2.1	14
224	Characterization of TCF3 rearrangements in pediatric B-lymphoblastic leukemia/lymphoma by mate-pair sequencing (MPseq) identifies complex genomic rearrangements and a novel TCF3/TEF gene fusion. Blood Cancer Journal, 2019, 9, 81.	2.8	14
225	Elucidating a false-negative MYC break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with IGH/MYC and IGH/BCL2 rearrangements. Journal of Physical Education and Sports Management, 2019, 5, a004077.	0.5	14
226	The significance of genetic mutations and their prognostic impact on patients with incidental finding of isolated del(20q) in bone marrow without morphologic evidence of a myeloid neoplasm. Blood Cancer Journal, 2020, 10, 7.	2.8	14
227	The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma. Clinical Cancer Research, 2021, 27, 5430-5439.	3.2	14
228	Targeted Next-Generation Sequencing in Polycythemia Vera and Essential Thrombocythemia. Blood, 2015, 126, 354-354.	0.6	14
229	Two novel factor IX promoter mutations: incremental progress towards â€˜saturation in vivo mutagenesisâ€™ of a human promoter region. Human Molecular Genetics, 1995, 4, 769-770.	1.4	13
230	A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOGâ€ACRIN cancer research group (E1908). American Journal of Hematology, 2016, 91, 308-312.	2.0	13
231	Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates. Blood Cancer Journal, 2017, 7, 657.	2.8	13
232	Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates. Leukemia and Lymphoma, 2018, 59, 2998-3001.	0.6	13
233	The Utilization of Chromosomal Microarray Technologies for Hematologic Neoplasms. American Journal of Clinical Pathology, 2018, 150, 375-384.	0.4	13
234	Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels. Blood Advances, 2018, 2, 1980-1984.	2.5	13

#	Article	IF	Citations
235	Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. American Journal of Hematology, 2019, 94, E117-E120.	2.0	13
236	Successful treatment of a child with T/myeloid acute bilineal leukemia associated with TLX3/BCL11B fusion and 9q deletion. Pediatric Blood and Cancer, 2011, 56, 467-469.	0.8	12
237	Expression of the Chemokine Receptor Gene, CCR8, is Associated With DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 580-589.	0.6	12
238	Concurrent activating <scp>KIT</scp> mutations in systemic mastocytosis. British Journal of Haematology, 2016, 173, 153-156.	1.2	12
239	Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms. Blood Cancer Journal, 2018, 8, 32.	2.8	12
240	A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow. American Journal of Clinical Pathology, 2018, 150, 421-431.	0.4	12
241	Substratification of patients with newly diagnosed standardâ€risk multiple myeloma. British Journal of Haematology, 2019, 185, 254-260.	1.2	12
242	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving postâ€autologous stem cell transplantation lenalidomide maintenance therapy. American Journal of Hematology, 2021, 96, E157-E162.	2.0	12
243	?Cryptic? dinucleotide polymorphism in the 3? region of the factor IX gene shows substantial variation among different populations. Human Genetics, 1994, 93, 357-358.	1.8	11
244	Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients. Leukemia Research, 2012, 36, 59-66.	0.4	11
245	Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: AASingle-Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 699-704.	0.2	11
246	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multiâ€parametric flow cytometry method. American Journal of Hematology, 2019, 94, 424-430.	2.0	11
247	The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularlyâ€annotated patients with primary myelofibrosis. American Journal of Hematology, 2019, 94, 299-305.	2.0	11
248	Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes. American Journal of Clinical Pathology, 2020, 153, 656-663.	0.4	11
249	Absence of somatic mosaicism in 17 families with hemophilia B: an analysis with a sensitivity 10- to 1000-fold greater than that of sequencing gels. Human Genetics, 1996, 98, 539-545.	1.8	10
250	Germline mutations in Peruvian patients with hemophilia B: Pattern of mutation in AmerIndians is similar to the putative endogenous germline pattern. Human Mutation, 1998, 11, 372-376.	1.1	10
251	Comprehensive validation of array comparative genomic hybridization platforms: how much is enough?. Genetics in Medicine, 2007, 9, 632-641.	1.1	10
252	Development of Five Dual-Color, Double-Fusion Fluorescence in Situ Hybridization Assays for the Detection of Common MLL Translocation Partners. Journal of Molecular Diagnostics, 2010, 12, 441-452.	1.2	10

#	Article	IF	Citations
253	CD36-positive B-lymphoblasts Predict Poor Outcome in Children With B-lymphoblastic Leukemia. Pediatric and Developmental Pathology, 2017, 20, 224-231.	0.5	10
254	Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirtyâ€nine patients. American Journal of Hematology, 2018, 93, 1347-1357.	2.0	10
255	Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. Blood Cancer Journal, 2019, 9, 20.	2.8	10
256	20+ Years and alive with primary myelofibrosis: Phenotypic signature of very longâ€lived patients. American Journal of Hematology, 2019, 94, 286-290.	2.0	10
257	ASXL1 and SETBP1 Mutations and Their Prognostic Contribution In Chronic Myelomonocytic Leukemia: An International Study Of 431 Patients. Blood, 2013, 122, 1510-1510.	0.6	10
258	A Case of Hairy Cell Leukemia With CCND1-IGH@ Translocation. American Journal of Surgical Pathology, 2011, 35, 1080-1084.	2.1	9
259	Cutaneous Extramedullary Plasmacytoma. American Journal of Dermatopathology, 2013, 35, 357-363.	0.3	9
260	A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy. Blood Cancer Journal, 2019, 9, 11.	2.8	9
261	De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. British Journal of Haematology, 2021, 195, 413-416.	1.2	9
262	The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their ALK, DUSP22 and TP63 Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis. Blood, 2017, 130, 822-822.	0.6	9
263	Application of Thrombolytic Drugs on Clotted Blood and Bone Marrow Specimens to Generate Usable Cells for Cytogenetic Analyses. Archives of Pathology and Laboratory Medicine, 2011, 135, 915-919.	1.2	9
264	The Effect of Number of Metaphases Studied and Abnormal Metaphase Percentage On Cytogenetic Risk Stratification in Primary Myelofibrosis. Blood, 2012, 120, 1742-1742.	0.6	9
265	Survival Trends in Essential Thrombocythemia in the Face of Changing Treatment Practices. Blood, 2015, 126, 2805-2805.	0.6	9
266	Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma. International Journal of Clinical and Experimental Pathology, 2012, 5, 72-6.	0.5	9
267	SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. Blood Advances, 2020, 4, 5716-5721.	2.5	9
268	Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases. Blood Cancer Journal, 2022, 12, 44.	2.8	9
269	Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. Leukemia Research, 2016, 50, 112-115.	0.4	8
270	FGFR1rearranged hematological neoplasms â€“ molecularly defined and clinically heterogeneous. Leukemia and Lymphoma, 2018, 59, 1520-1522.	0.6	8

#	Article	IF	Citations
271	Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis. American Journal of Hematology, 2018, 93, E235-E238.	2.0	8
272	Myeloid Sarcoma With CBFB-MYH11 Fusion (inv(16) or t(16;16)) Prevails in the Abdomen. American Journal of Clinical Pathology, 2020, 153, 333-341.	0.4	8
273	Constitutional chromosome rearrangements that mimic the 2017 world health organization â€œacute myeloid leukemia with recurrent genetic abnormalitiesâ€: A study of three cases and review of the literature. Cancer Genetics, 2019, 230, 37-46.	0.2	8
274	Fluorescence inâ€situ hybridisation for TP63 rearrangements in T cell lymphomas: singleâ€site experience of 470 patients and implications for clinical testing. Histopathology, 2020, 76, 481-485.	1.6	8
275	Molecular and phenotypic characterization of an early T-cell precursor acute lymphoblastic lymphoma harboring PICALM-MLLT10 fusion with aberrant expression of B-cell antigens. Cancer Genetics, 2020, 240, 40-44.	0.2	8
276	Detection of cryptic CCND1 rearrangements in mantle cell lymphoma by next generation sequencing. Annals of Diagnostic Pathology, 2020, 46, 151533.	0.6	8
277	Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. Leukemia, 2021, 35, 644-649.	3.3	8
278	Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. Blood Cancer Journal, 2021, 11, 18.	2.8	8
279	Clinical utility of next generation sequencing to detect IGH/IL3 rearrangements [t(5;14)(q31.1;q32.1)] in B-lymphoblastic leukemia/lymphoma. Annals of Diagnostic Pathology, 2021, 53, 151761.	0.6	8
280	A leukemic presentation of a â€œtriple-hitâ€•lymphoma. Blood, 2014, 123, 1126-1126.	0.6	7
281	Is It Time for a New Gold Standard? FISH vs Cytogenetics in AML DiagnosisThe Authorsâ€™ Reply. American Journal of Clinical Pathology, 2016, 145, 430-432.	0.4	7
282	The 2016 revised World Health Organization definition of â€˜myelodysplastic syndrome with isolated del(5q)â€™; prognostic implications of single versus double cytogenetic abnormalities. British Journal of Haematology, 2017, 178, 57-60.	1.2	7
283	Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1 / PDGFRA rearrangement. Cancer Genetics, 2018, 220, 13-18.	0.2	7
284	Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates. Blood Cancer Journal, 2018, 8, 118.	2.8	7
285	Combined Tumors in Hematolymphoid Neoplasms: Case Series of Histiocytic and Langerhans Cell Sarcomas Arising From Low-Grade B-Cell Lymphoma. BMC Clinical Pathology, 2019, 12, 2632010X1987841.	0.7	7
286	Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. American Journal of Hematology, 2019, 94, 5-9.	2.0	7
287	Use of mate-pair sequencing to characterize a complex cryptic BCR/ABL1 rearrangement observed in a newly diagnosed case of chronic myeloid leukemia. Human Pathology, 2019, 89, 109-114.	1.1	7
288	Characterization of a cryptic PML-RARA fusion by mate-pair sequencing in a case of acute promyelocytic leukemia with a normal karyotype and negative RARA FISH studies. Leukemia and Lymphoma, 2020, 61, 975-978.	0.6	7

#	Article	IF	Citations
289	Cryptic and atypical <scp>KMT2Aâ€‰USP2</scp> and <scp>KMT2Aâ€‰USP8</scp> rearrangements identified by mate pair sequencing in infant and childhood leukemia. Genes Chromosomes and Cancer, 2020, 59, 422-427.	1.5	7
290	Acute myeloid leukemia after age 70â€‰years: A retrospective comparison of survival following treatment with intensive versus <scp>HMA</scp>â€‰Â±â€‰venetoclax chemotherapy. American Journal of Hematology, 2021, 96, E108-E111.	2.0	7
291	Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple Myeloma. Blood, 2013, 122, 3210-3210.	0.6	7
292	Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902. Blood, 2015, 126, 1308-1308.	0.6	7
293	Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: Clinical correlates and effect on imatinib mesylate treatment outcome. Leukemia and Lymphoma, 2007, 48, 2137-2140.	0.6	6
294	Development of an NPM1/MLF1 D-FISH Probe Set for the Detection of t(3;5)(q25;q35) Identified in Patients with Acute Myeloid Leukemia. Journal of Molecular Diagnostics, 2014, 16, 527-532.	1.2	6
295	Mantle cell lymphoma with a novel t(11;12)(q13;p11.2): a proposed alternative mechanism of CCND1 up-regulation. Human Pathology, 2017, 64, 207-212.	1.1	6
296	Characterizing false-positive fluorescence in situ hybridization results by mate-pair sequencing in a patient with chronic myeloid leukemia and progression to myeloid blast crisis. Cancer Genetics, 2020, 243, 48-51.	0.2	6
297	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 46.	2.8	6
298	Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted. Leukemia, 2021, 35, 3329-3333.	3.3	6
299	Risk Factors for Arterial Versus Venous Thrombosis in Polycythemia Vera: Single Center Experience in 587 Patients. Blood, 2016, 128, 948-948.	0.6	6
300	Prognostic significance of acquired 1q22 gain in multiple myeloma. American Journal of Hematology, 2021, , .	2.0	6
301	MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma. Blood Cancer Journal, 2021, 11, 184.	2.8	6
302	Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (<scp>MDSâ€RS</scp>) but not in <scp>MDS</scp>/<scp>MPNâ€RSâ€T</scp>. American Journal of Hematology, 2022, 97, .	2.0	6
303	Characterization of a rarely reported STAT5B/RARA gene fusion in a young adult with newly diagnosed acute promyelocytic leukemia with resistance to ATRA therapy. Cancer Genetics, 2019, 237, 51-54.	0.2	5
304	Identification of a novel <scp>KMT2A</scp>/<scp>GIMAP8</scp> gene fusion in a pediatric patient with acute undifferentiated leukemia. Genes Chromosomes and Cancer, 2021, 60, 108-111.	1.5	5
305	CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. Blood Cancer Journal, 2021, 11, 54.	2.8	5
306	Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV). Blood, 2018, 132, 578-578.	0.6	5

#	Article	IF	Citations
307	Decreased Levels of Total or HDL Cholesterol in Primary Myelofibrosis Are Associated with Shortened Survival: DIPSS-Plus Independent Prognostic Value.. Blood, 2012, 120, 2851-2851.	0.6	5
308	Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study. Blood, 2013, 122, 2777-2777.	0.6	5
309	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. Blood Cancer Journal, 2022, 12, 26.	2.8	5
310	Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML. Leukemia Research, 2022, 116, 106818.	0.4	5
311	ADDENDUM: Section E9 of the American College of Medical Genetics Technical Standards and Guidelines: Fluorescence in situ hybridization. Genetics in Medicine, 2019, 21, 2405.	1.1	4
312	Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900. Haematologica, 2019, 104, e147-e150.	1.7	4
313	Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis. Leukemia, 2019, 33, 780-785.	3.3	4
314	Clinical utility of fluorescence in situ hybridizationâ€based diagnosis of BCRâ€ABL1 like (<scp>P</scp>hiladelphia chromosome like) <scp>B</scp>â€cute lymphoblastic leukemia. American Journal of Hematology, 2020, 95, E68-E72.	2.0	4
315	Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISHâ€based algorithm distinguishes prognostic groups and outcomes. Blood Cancer Journal, 2021, 11, 156.	2.8	4
316	Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival. Blood, 2016, 128, 1123-1123.	0.6	4
317	Identification of t(1;19)(q12;p13) and ploidy changes in an ependymosarcoma: a cytogenetic evaluation. , 2012, 31, 142-145.		4
318	Discovery of 6 Novel Translocations Involving the Imatinib Responsive Genes PDGFRB and PDGFRB from Screening 29,047 Abnormal Bone Marrow Specimens.. Blood, 2004, 104, 2902-2902.	0.6	4
319	Gene Expression Profiling Identifies Distinct Signatures for Dysplastic and Proliferative Chronic Myelomonocytic Leukemia. Blood, 2016, 128, 110-110.	0.6	4
320	The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis. Blood, 2018, 132, 1761-1761.	0.6	4
321	<scp>RNAseq</scp> identification of <scp>FISH</scp> â€cryptic <scp>BCL6</scp> :: <scp>TP63</scp> rearrangement in <scp>ALK</scp> â€negative anaplastic large cell lymphoma. Histopathology, 2022, , .	1.6	4
322	PRE: a novel element with the hallmarks of a retrotransposon derived from an unknown structural RNA. Nucleic Acids Research, 1992, 20, 5233-5233.	6.5	3
323	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3â€ITD mutational status. American Journal of Hematology, 2018, 93, E401-E404.	2.0	3
324	A nearâ€haploid clone harboring a BCR/ABL1 gene fusion in an adult patient with newly diagnosed Bâ€lymphoblastic leukemia. Genes Chromosomes and Cancer, 2019, 58, 665-668.	1.5	3

#	Article	IF	Citations
325	Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion. Cancer Genetics, 2020, 241, 67-71.	0.2	3
326	Phenotypic correlates and prognostic outcomes of <scp>TET2</scp> mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. American Journal of Hematology, 2020, 95, E86-E89.	2.0	3
327	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. Blood, 2013, 122, 104-104.	0.6	3
328	Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series. Blood, 2016, 128, 2798-2798.	0.6	3
329	Monocytosis Is a Powerful and Independent Predictor of Shortened Overall and Leukemia-Free Survival in Primary Myelofibrosis. Blood, 2016, 128, 4249-4249.	0.6	3
330	Conventional Cytogenetic Analysis of Hematologic Neoplasms: A 20-Year Review of Proficiency Test Results From the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee. Archives of Pathology and Laboratory Medicine, 2021, 145, 176-190.	1.2	3
331	Indolent Mantle Cell Lymphoma: A Distinct Subgroup Characterized by Leukemic Phase Disease without Lymphadenopathy.. Blood, 2009, 114, 3937-3937.	0.6	3
332	Normal Karyotype Primary Myelofibrosis (NK-PMF): Clinical and Molecular Prognostication In 690 Patients. Blood, 2013, 122, 1587-1587.	0.6	3
333	"Proliferative" Versus "Dysplastic" Chronic Myelomonocytic Leukemia: Molecular and Prognostic Correlates. Blood, 2016, 128, 1987-1987.	0.6	3
334	<i>SF3B1</i>-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. Haematologica, 2022, 107, 1189-1192.	1.7	3
335	Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate. British Journal of Haematology, 2003, 123, 366-367.	1.2	2
336	When are apparently non-clonal abnormalities in bone marrow chromosome studies actually clonal?. Cancer Genetics, 2012, 205, 405-409.	0.2	2
337	Sustained remission in a patient with myelodysplastic syndrome and a complex karyotype after erythropoiesis-stimulating therapy followed by colonic T-cell lymphoblastic lymphoma. Leukemia and Lymphoma, 2013, 54, 1534-1537.	0.6	2
338	Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma. European Journal of Haematology, 2013, 91, 193-195.	1.1	2
339	Immunophenotypic and laboratory features of t(11;14)(q13;q32)-positive plasma cell neoplasms. Leukemia and Lymphoma, 2018, 59, 1913-1919.	0.6	2
340	Biphenotypic Acute Leukemia versus Myeloid Antigen-Positive ALL: Clinical Relevance of WHO Criteria for Mixed Phenotype Acute Leukemia. Case Reports in Hematology, 2018, 2018, 1-4.	0.3	2
341	Practiceâ€relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm. American Journal of Hematology, 2018, 93, E383-E386.	2.0	2
342	Whole Genome Mate-pair Sequencing of Plasma Cell Neoplasm as a Novel Diagnostic Strategy: AÂCase of Unrecognized t(2;11) Structural Variation. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 598-602.	0.2	2

#	Article	IF	Citations
343	Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma. Genes Chromosomes and Cancer, 2021, 60, 678-686.	1.5	2
344	A rare case of atypical chronic myeloid leukemia associated with t(8;22)(p11.2;q11.2)/ BCR-FGFR1 rearrangement: A case report and literature review. Cancer Genetics, 2021, 258-259, 69-73.	0.2	2
345	SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value. Blood, 2011, 118, 460-460.	0.6	2
346	R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission. Blood, 2012, 120, 676-676.	0.6	2
347	ASXL1 and CBL Mutations Are Independently Predictive of Inferior Survival in Advanced Systemic Mastocytosis. Blood, 2015, 126, 828-828.	0.6	2
348	Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements". Blood, 2016, 128, 1750-1750.	0.6	2
349	Prefibrotic Versus Overtly Fibrotic Primary Myelofibrosis: Clinical, Cytogenetic, Molecular and Prognostic Comparisons. Blood, 2016, 128, 4247-4247.	0.6	2
350	Histologic and Immunohistochemical Study of Bone Marrow Monocytic Nodules in 21 Cases With Myelodysplasia. American Journal of Clinical Pathology, 2003, 120, 874-881.	0.4	2
351	ASXL1 Mutations in Myelodysplastic Syndromes with 1% or More Ring Sideroblasts: Prevalence, Clinical Correlates and Prognostic Relevance. Blood, 2015, 126, 2882-2882.	0.6	2
352	The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes. American Journal of Hematology, 2018, 93, E164-E167.	2.0	1
353	Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?. Blood Cancer Journal, 2018, 8, 8.	2.8	1
354	Revisiting the need for bone marrow examination in chronic myeloid leukemia. American Journal of Hematology, 2018, 93, 5-7.	2.0	1
355	Genetic predictors of response to specific drugs in primary myelofibrosis. Blood Cancer Journal, 2018, 8, 120.	2.8	1
356	Characterization of a cryptic KMT2A/AFF1 gene fusion by mate-pair sequencing (MPseq) in a young adult with newly diagnosed B-lymphoblastic leukemia. Journal of Hematopathology, 2019, 12, 99-104.	0.2	1
357	Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies. Leukemia, 2019, 33, 2522-2553.	3.3	1
358	Siblings with ETV6/RUNX1-positive B-lymphoblastic leukemia: A single site experience and review of the literature. Annals of Diagnostic Pathology, 2020, 48, 151588.	0.6	1
359	Anaplastic large-cell lymphoma (ALK-negative)-related heart failure and recurrence after heart transplantation. Journal of Heart and Lung Transplantation, 2020, 39, 1156-1158.	0.3	1
360	20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients. Blood, 2018, 132, 4301-4301.	0.6	1

#	Article	IF	Citations
361	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Blood, 2018, 132, 3035-3035.	0.6	1
362	Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study. Blood, 2018, 132, 3040-3040.	0.6	1
363	14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (clg-FISH).. Blood, 2007, 110, 2477-2477.	0.6	1
364	Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival. Blood, 2013, 122, 2821-2821.	0.6	1
365	Driver Mutations and Prognosis in 502 Patients with Essential Thrombocythemia. Blood, 2015, 126, 1599-1599.	0.6	1
366	Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis. Blood, 2015, 126, 2801-2801.	0.6	1
367	A 27-Gene NGS Panel in Primary Myelofibrosis Identifies ASXL1, CBL, RUNX1 and SRSF2 Mutations As Being Unfavorable and Absence of Any Non-Driver Mutation As Being Favorable to Survival. Blood, 2015, 126, 350-350.	0.6	1
368	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). Blood, 2016, 128, 155-155.	0.6	1
369	Abnormal Karyotype and Prognosis in Polycythemia Vera: A Single Center Experience in 239 Informative Cases. Blood, 2016, 128, 3115-3115.	0.6	1
370	U2AF1 Mutation Variants and Their Phenotypic and Prognostic Relevance in Primary Myelofibrosis. Blood, 2016, 128, 4248-4248.	0.6	1
371	Number and Type of TET2 Mutations in Chronic Myelomonocytic Leukemia: Clinical and Prognostic Correlates. Blood, 2016, 128, 4343-4343.	0.6	1
372	OUP accepted manuscript. Laboratory Medicine, 2021, , .	0.8	1
373	Low Level Amplification (Duplication) of 1q21 in Myeloma and Prognosis; the Role of CKS1B.. Blood, 2005, 106, 624-624.	0.6	1
374	Low Incidence of FIP1L1-PDGFRA in Eosinophilic Patients and Long-Term Experience with Imatinib Therapy.. Blood, 2005, 106, 2590-2590.	0.6	1
375	Anaplastic Angiocentric Glioma: A Report of Two Cases. FASEB Journal, 2008, 22, 706.4.	0.2	1
376	Immunoglobulin Free Light Chain Levels Predict Survival in Primary Myelofibrosis and De Novo Myelodysplastic Syndromes. Blood, 2011, 118, 1756-1756.	0.6	1
377	Monosomal Karyotype Predicts Adverse Prognosis In Patients With Chronic Myelomonocytic Leukemia. Blood, 2013, 122, 1334-1334.	0.6	1
378	Unique Clinical Epidemiologic Risk Factors Are Associated with Distinct Methylation Subgroups in Newly-Diagnosed Acute Myeloid Leukemia (AML). Blood, 2016, 128, 1719-1719.	0.6	1

#	Article	IF	Citations
379	Subnormal Lymphocyte Count Predicts Inferior Survival in Myelodysplastic Syndromes: A Single Center Experience in 889 Patients. Blood, 2016, 128, 5534-5534.	0.6	1
380	Identification of Serum Lactate Dehydrogenase (LDH) As an Independent Prognostic Biomarker in Polycythemia Vera. Blood, 2016, 128, 3111-3111.	0.6	1
381	Novel Mutations in NOTCH and Altered Wnt/Î²-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia. Blood, 2016, 128, 4103-4103.	0.6	1
382	High Level MYC Amplification in Aggressive B-Cell Lymphomas: Is It a Marker of Aggressive Disease?. Blood, 2018, 132, 1693-1693.	0.6	1
383	Association of Clinical Epidemiologic Exposures and Overall Survival with Genome-Wide DNA Methylation Profiles in Acute Myeloid Leukemia: Analysis of the Mayo Clinic AML Epidemiology Cohort. Blood, 2018, 132, 3987-3987.	0.6	1
384	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. Blood, 2019, 134, 1800-1800.	0.6	1
385	Characterization of Atypical t(11;14) CCND1/IGH Translocations in Multiple Myeloma. Blood, 2021, 138, 3771-3771.	0.6	1
386	Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. Blood, 2021, 138, 3368-3368.	0.6	1
387	Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia. Leukemia, 2022, 36, 1693-1696.	3.3	1
388	Identification of EWSR1 rearrangements in patients with immature hematopoietic neoplasms: A case series and review of literature. Annals of Diagnostic Pathology, 2022, 58, 151942.	0.6	1
389	Apparent coexistence of ETV6::RUNX1 and KMT2A::MLLT3 fusions due to a nonproductive KMT2A rearrangement in B-ALL. Leukemia and Lymphoma, 2022, , 1-4.	0.6	1
390	Characterization of a t(1;2)(p36;p21) involving the PRDM16 gene region by mate-pair sequencing (MPseq) in a patient with newly diagnosed acute myeloid leukemia with myelodysplasia-related changes. Journal of Hematopathology, 2019, 12, 85-90.	0.2	0
391	Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. Leukemia Research, 2019, 87, 106264.	0.4	0
392	Calculatorâ€free pointâ€ofâ€care prognostication in myelodysplastic syndromes. American Journal of Hematology, 2019, 94, E99-E101.	2.0	0
393	Lymphoma-like double-hit genetic abnormalities (MYC/IGH and IGH/BCL2) in a case of non-secretory multiple myeloma. Leukemia and Lymphoma, 2021, 62, 243-246.	0.6	0
394	Dual Primary IGH Translocations in Multiple Myeloma: A Novel Finding. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e710-e713.	0.2	0
395	Bone Marrow Histologic and Cytogenetic Changes during Leukemic Transformation of Myelofibrosis with Myeloid Metaplasia.. Blood, 2004, 104, 4750-4750.	0.6	0
396	Additional Cytogenetic Abnormalities and/or Philadelphia Chromosome Metaphase Mosaicism Might Adversely Influence Survival and Imatinib Response in Chronic Myeloid Leukemia.. Blood, 2006, 108, 4783-4783.	0.6	0

#	Article	IF	Citations
397	â€™Idiopathicâ€™ Eosinophilia with an Occult T-Cell Clone: Prevalence, FIP1L1-PDGFRA Status, and Clinical Course.. Blood, 2006, 108, 2701-2701.	0.6	0
398	Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation.. Blood, 2006, 108, 3587-3587.	0.6	0
399	Peripheral Blood Cytogenetic Studies in Hematological Neoplasms: Predictors of Obtaining Metaphases for Analysis.. Blood, 2007, 110, 3504-3504.	0.6	0
400	Deletion 5q in AML: A Clinicopathological Description of 79 Cases from a Single Institution. Blood, 2008, 112, 2523-2523.	0.6	0
401	Mechanisms of the Formation of Multinuclear Malignant Plasma Cells in the Novel AL/MM Human Cell Lines, ALMC-1 and ALMC-2: Implications for Tumor Cell Growth Control.. Blood, 2008, 112, 1707-1707.	0.6	0
402	Rearrangements of IER3 Represent a Novel and Recurrent Molecular Abnormality in Myelodysplastic Syndromes (MDS). Blood, 2008, 112, 2679-2679.	0.6	0
403	Isolated Trisomy 8 in the Myelodysplastic Syndromes.. Blood, 2009, 114, 2785-2785.	0.6	0
404	Evidence for Cytogenetic and Fluorescence in Situ Hybridization (FISH) Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies.. Blood, 2009, 114, 1802-1802.	0.6	0
405	Autologous Hematopoietic Cell Transplantation as Consolidation for Younger Patients with Acute Myeloid Leukemia in First Complete Remission: Follow-up of E1900.. Blood, 2009, 114, 3405-3405.	0.6	0
406	The Impact of Obesity on the Presentation & Outcome of Adult Acute Myeloid Leukemia (AML) - ECOG Studies E1900 & E3999. Blood, 2011, 118, 2568-2568.	0.6	0
407	Young Adults Presenting with Extramedullary Acute Myeloid Leukemia Have A Unique Sensitivity to High Doses of Anthracyclines: Subset Analysis of ECOG 1900,. Blood, 2011, 118, 3619-3619.	0.6	0
408	Differential Prognostic Effect of IDH1 Versus IDH2 Mutations in Myelodysplastic Syndromes: A Mayo Clinic Study of 277 Patients. Blood, 2011, 118, 971-971.	0.6	0
409	TP53 mutations and Polymorphisms in Primary Myelofibrosis,. Blood, 2011, 118, 3840-3840.	0.6	0
410	Spliceosome Mutations Involving SRSF2, SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis. Blood, 2012, 120, 1711-1711.	0.6	0
411	Phenotypic and Prognostic Correlates of Spliceosome Mutations (SRSF2, SF3B1, U2AF35) in Chronic Myelomonocytic Leukemia with â‰¥ 1% Ring Sideroblasts.. Blood, 2012, 120, 2803-2803.	0.6	0
412	Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML. Blood, 2012, 120, 1875-1875.	0.6	0
413	Survival and Prognosis in World Health Organization Defined Chronic Myelomonocytic Leukemia- A Mayo Clinic Series of 227 Patients. Blood, 2012, 120, 3790-3790.	0.6	0
414	Prognostic Interactions Between SRSF2, ASXL1, and IDH Mutations in Primary Myelofibrosis and Determination of Added Value to Cytogenetic Risk Stratification and DIPSS-Plus. Blood, 2012, 120, 430-430.	0.6	0

#	Article	IF	Citations
415	T(8;9)(p22;p24)/PCM1-JAK2 Activates SOCS2 and SOCS3 Via STAT5. Blood, 2012, 120, 1567-1567.	0.6	0
416	U2AF1 mutations In Primary Myelofibrosis Cluster With Normal Karyotype and JAK2V617F and Are Strongly Associated With Anemia and Thrombocytopenia. Blood, 2013, 122, 4060-4060.	0.6	0
417	Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience. Blood, 2013, 122, 4955-4955.	0.6	0
418	Copy Number Abnormalities Of The Interferon Regulatory Factor-4 (IRF4) Gene Are Associated With IRF4/MUM1 Expression In Peripheral T-Cell Lymphomas. Blood, 2013, 122, 3016-3016.	0.6	0
419	Vascular Events and Risk Factors for Thrombosis in Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T). Blood, 2015, 126, 4067-4067.	0.6	0
420	Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. Blood, 2015, 126, 4062-4062.	0.6	0
421	Molecular Correlates of Anemia in Primary Myelofibrosis. Blood, 2015, 126, 4068-4068.	0.6	0
422	Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment. Blood, 2015, 126, 2875-2875.	0.6	0
423	Prognostic Interaction Between ASXL1 and TET2 Mutations in Chronic Myelomonocytic Leukemia. Blood, 2015, 126, 2864-2864.	0.6	0
424	Clinical Outcome of Therapy-Related Acute Myeloid Leukemia Is Strongly Related to Cytogenetic Analysis. Blood, 2015, 126, 1401-1401.	0.6	0
425	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. Blood, 2015, 126, 4176-4176.	0.6	0
426	Prognostic Impact of Bone Marrow Fibrosis in Polycythemia Vera: Validation of the IWG-MRT Study and Additional Observations. Blood, 2016, 128, 3129-3129.	0.6	0
427	Prognostic Relevance of Monocytopenia and Lymphocyte-to-Monocyte Ratio in Primary Myelodysplastic Syndromes. Blood, 2016, 128, 1996-1996.	0.6	0
428	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2016, 128, 5615-5615.	0.6	0
429	Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates. Blood, 2016, 128, 4259-4259.	0.6	0
430	Utilization of Mate-Pair Sequencing to Characterize Complex and Novel TCF3 Translocations. Blood, 2016, 128, 4086-4086.	0.6	0
431	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. Blood, 2016, 128, 3269-3269.	0.6	0
432	Next-Generation Sequencing in Myelodysplastic Syndromes: Prognostic Interaction Between Adverse Mutations and IPSS-R. Blood, 2016, 128, 1986-1986.	0.6	0

#	Article	IF	Citations
433	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. Blood, 2016, 128, 3255-3255.	0.6	0
434	DNTM3A Mutations and Prognosis in Chronic Myelomonocytic Leukemia. Blood, 2016, 128, 1988-1988.	0.6	0
435	Evaluation of Revised International Staging System for Transplant-Eligible Multiple Myeloma Patients. Blood, 2016, 128, 3452-3452.	0.6	0
436	The 2016 Revised World Health Organization Classification of 'Myelodysplastic Syndrome with Isolated Del(5q)'; Prognostic Implications of Single Versus Double Cytogenetic Abnormalities. Blood, 2016, 128, 5542-5542.	0.6	0
437	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.	0.6	0
438	Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis. Blood, 2018, 132, 4300-4300.	0.6	0
439	Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates. Blood, 2018, 132, 3034-3034.	0.6	0
440	Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide. Blood, 2018, 132, 4287-4287.	0.6	0
441	Clinical and Molecular Models of Prognostication in Mastocytosis: Analysis Based on 580 Consecutive Cases. Blood, 2018, 132, 582-582.	0.6	0
442	Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis. Blood, 2018, 132, 1767-1767.	0.6	0
443	Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases. Blood, 2018, 132, 3050-3050.	0.6	0
444	Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger. Blood, 2018, 132, 3033-3033.	0.6	0
445	Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies. Blood, 2018, 132, 4291-4291.	0.6	0
446	Frequency of Acquired Genetic Mutations and Their Prognostic Impact on Patients with Incidental Finding of Isolated 20q- in Bone Marrow without Morphologic Evidence of a Myeloid Neoplasm. Blood, 2018, 132, 4382-4382.	0.6	0
447	MPL-Mutated Essential Thrombocythemia: A Morphologic Reappraisal. Blood, 2018, 132, 3036-3036.	0.6	0
448	Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with Myeloproliferative Neoplasm Associated-Driver Mutations. Blood, 2018, 132, 3100-3100.	0.6	0
449	Efficacy of Mitoxantrone-Based Salvage Therapies in Relapsed or Refractory Acute Myeloid Leukemia in the Mayo Clinic Cancer Center: Analysis of Survival after CLAG-M Vs. MEC. Blood, 2018, 132, 2678-2678.	0.6	0
450	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. Blood, 2018, 132, 2689-2689.	0.6	0

#	Article	IF	Citations
451	Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events. Blood, 2018, 132, 3044-3044.	0.6	0
452	A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy. Blood, 2018, 132, 1771-1771.	0.6	0
453	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 4396-4396.	0.6	0
454	Recurrent Chromosomal Abnormalities in Tumoral Lesions of Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia: A Large-Scale Fluorescent in-Situ Hybridization Study on Tissue Biopsy Sections. Blood, 2019, 134, 4282-4282.	0.6	0
455	Differentiating between Hyperdiploidy and Pseudo-Hyperdiploidy in B-Lymphoblastic Leukemia Utilizing Low-Coverage Mate-Pair Sequencing. Blood, 2019, 134, 5212-5212.	0.6	0
456	Utilizing next-generation sequencing to characterize a case of acute myeloid leukemia with t(4;12)(q12;p13) in the absence of ETV6/CHIC2 and ETV6/PDGFRA gene fusions. Cancer Genetics, 2021, 260-261, 1-5.	0.2	0
457	Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. Blood, 2021, 138, 1267-1267.	0.6	0
458	Cytogenetics in Essential Thrombocythemia: Phenotype and Molecular Correlates and Prognostic Relevance in 818 Informative Cases. Blood, 2021, 138, 3629-3629.	0.6	0
459	Cryptic t(6;11) KMT2A rearrangement in a pediatric acute myeloid leukemia patient detected by nextâ€generation sequencing and dualâ€fusion FISH analysis. Pediatric Blood and Cancer, 2022, 69, e29428.	0.8	0
460	False-Negative Centromere 15 Probe Results in Association with African Ancestry in Plasma Cell Dyscrasias. Blood, 2021, 138, 4101-4101.	0.6	0
461	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. Blood, 2020, 136, 9-10.	0.6	0
462	Heterogeneity of MYC Abnormalities in Multiple Myeloma. Blood, 2020, 136, 2-3.	0.6	0
463	Clinical Value of Next Generation Sequencing in the Detection of Recurring Structural Rearrangements and Copy Number Abnormalities in Acute Myeloid Leukemia. Blood, 2020, 136, 21-22.	0.6	0
464	Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 rearrangements in Anaplastic Large Cell Lymphoma. Blood, 2020, 136, 22-23.	0.6	0